Matt Hoffman

Ongoing surveillance from the CDC and FDA will continue to evaluate the risk of Guillan-Barré syndrome to guide further ACIP recommendations.

Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.

The study findings imply newly available prevention strategies for which older children—ages 2 to 5 years—are not currently eligible should be prioritized.

New research has suggested that Alzheimer disease pathology may be driven by an infectious agent, Porphyromonas gingivalis.

Congress has voted to pass the right-to-try bill, which will provide terminally ill patients with the ability to seek out experimental therapies not yet approved by the FDA.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

At CROI 2018, Dr. Patricia Flynn discussed the impact of ART on individuals with perinatal HIV infections, and how far the infectious disease community has come since its initial use.

The medical community has learned many lessons by looking back on the early days of the HIV/AIDS epidemic, including the value of multidisciplinary teams, the vital role of acute care clinicians, and more.

Amid alleged tobacco investments, Brenda Fitzgerald has resigned from her position as director of the CDC.

Can a prior pharmaceutical company president successfully address ever-climbing medication costs in the United States?

The test combines the convenience of the saliva test with the reliability of the blood test.

The FDA recently issued a Compounding Risk Alert related to a rare, adverse event associated with compounded triamcinolone, moxifloxacin, and vancomycin: potential blindness.